α-synuclein in the pathophysiology of Alzheimer’s disease

被引:0
|
作者
Daniel Twohig
Henrietta M. Nielsen
机构
[1] Stockholm University,Department of Biochemistry and Biophysics
关键词
α-synuclein; Alzheimer’s disease; Lewy pathology; tau;
D O I
暂无
中图分类号
学科分类号
摘要
The Alzheimer’s disease (AD) afflicted brain is neuropathologically defined by extracellular amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau protein. However, accumulating evidence suggests that the presynaptic protein α-synuclein (αSyn), mainly associated with synucleinopathies like Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), is involved in the pathophysiology of AD. Lewy-related pathology (LRP), primarily comprised of αSyn, is present in a majority of autopsied AD brains, and higher levels of αSyn in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD have been linked to cognitive decline. Recent studies also suggest that the asymptomatic accumulation of Aβ plaques is associated with higher CSF αSyn levels in subjects at risk of sporadic AD and in individuals carrying autosomal dominant AD mutations. Experimental evidence has further linked αSyn mainly to tau hyperphosphorylation, but also to the pathological actions of Aβ and the APOEε4 allele, the latter being a major genetic risk factor for both AD and DLB. In this review, we provide a summary of the current evidence proposing an involvement of αSyn either as an active or passive player in the pathophysiological ensemble of AD, and furthermore describe in detail the current knowledge of αSyn structure and inferred function.
引用
收藏
相关论文
共 50 条
  • [1] α-synuclein in the pathophysiology of Alzheimer's disease
    Twohig, Daniel
    Nielsen, Henrietta M.
    MOLECULAR NEURODEGENERATION, 2019, 14 (1)
  • [2] Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
    Larson, Megan E.
    Sherman, Mathew A.
    Greimel, Susan
    Kuskowski, Michael
    Schneider, Julie A.
    Bennett, David A.
    Lesne, Sylvain E.
    JOURNAL OF NEUROSCIENCE, 2012, 32 (30): : 10253 - 10266
  • [3] α-synuclein, Aβ and Alzheimer's disease
    Wirths, O
    Bayer, TA
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (01): : 103 - 108
  • [4] The pathophysiology of Alzheimer's disease
    Roberts, GW
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P380 - P380
  • [5] Pathophysiology of Alzheimer's disease
    Sanchez Mario, Alvarez
    Ivonne, Pedroso
    Amado, de la Fe
    Sanchez Arnoldo, Padron
    Sanchez Marilet, Alvarez
    Lazaro, Alvarez
    REVISTA MEXICANA DE NEUROCIENCIA, 2008, 9 (03): : 196 - 201
  • [6] Pathophysiology of Alzheimer's Disease
    Yarns, Brandon C.
    Holiday, Kelsey A.
    Carlson, David M.
    Cosgrove, Coleman K.
    Melrose, Rebecca J.
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2022, 45 (04) : 663 - 676
  • [7] Pathophysiology of Alzheimer's disease
    Imbimbo, BP
    Lombard, J
    Pomara, N
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2005, 15 (04) : 727 - +
  • [8] Approach to the pathophysiology of Alzheimer's disease
    Lucia Jimenez, Martha
    UNIVERSITAS MEDICA, 2005, 46 (01): : 22 - 26
  • [9] Alzheimer's disease pathophysiology in the Retina
    Gaire, Bhakta Prasad
    Koronyo, Yosef
    Fuchs, Dieu-Trang
    Shi, Haoshen
    Rentsendorj, Altan
    Danziger, Ron
    Vit, Jean-Philippe
    Mirzaei, Nazanin
    Doustar, Jonah
    Sheyn, Julia
    Hampel, Harald
    Vergallo, Andrea
    Davis, Miyah R.
    Jallow, Ousman
    Baldacci, Filippo
    Verdooner, Steven R.
    Barron, Ernesto
    Mirzaei, Mehdi
    Gupta, Vivek K.
    Graham, Stuart L.
    Tayebi, Mourad
    Carare, Roxana O.
    Sadun, Alfredo A.
    Miller, Carol A.
    Dumitrascu, Oana M.
    Lahiri, Shouri
    Gaon, Liang
    Black, Keith L.
    Koronyo-Hamaoui, Maya
    PROGRESS IN RETINAL AND EYE RESEARCH, 2024, 101
  • [10] Somatostatin and the pathophysiology of Alzheimer's disease
    Almeida, Victor N.
    AGEING RESEARCH REVIEWS, 2024, 96